Revolution Medicines Inc
revmed.comRevolution Medicines Inc (NASDAQ: RVMD) is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company generates no product revenue as of the 10-K filed 2026-02-25, operating entirely on capital raises to fund research and development. Its pipeline is built around proprietary RAS(ON) Inhibitors, small molecules that bind directly to the active, GTP-bound form of RAS using a tri-complex technology platform. Lead candidates include daraxonrasib (pan-RAS(ON) inhibitor), zoldonrasib (KRAS G12D-selective, received FDA Breakthrough Therapy Designation in December 2025), and elironrasib (KRAS G12C-selective, received FDA Breakthrough Therapy Designation in July 2025). Primary target indications are pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Three Phase 3 registrational studies in PDAC (RASolute 302, 303, 304, 305) were active as of the filing date. The company is headquartered in the United States and lists on the Nasdaq Global Select Market.
Products & Services
Daraxonrasib: pan-RAS(ON) tri-complex inhibitor in Phase 3 trials for PDAC and Phase 1/combination studies for NSCLC. Zoldonrasib: oral KRAS G12D-selective RAS(ON) inhibitor, FDA Breakthrough Therapy Designation December 2025 for KRAS G12D-mutated locally advanced or metastatic NSCLC. Elironrasib: oral KRAS G12C-selective RAS(ON) inhibitor, FDA Breakthrough Therapy Designation July 2025 for KRAS G12C-mutated locally advanced or metastatic NSCLC.
Revenue Model
No product revenue. Pre-commercial stage company funded through equity capital. No disclosed partnership or royalty revenue streams in the filing excerpts.
Customers & Markets
No commercial customers as of filing date. Target patient populations are adults with RAS-mutated cancers, specifically KRAS G12D and KRAS G12C mutations, across PDAC and NSCLC indications.
Geographic Exposure
United States headquarters. Global Phase 3 registrational studies referenced in filing excerpts. No specific geographic revenue breakdown applicable given pre-commercial status.
Financial Snapshot
Loading...
